Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD22 | P20273 | 11/20 | 0.35 |
| ▸ | MAG | P20916 | 3/20 | 0.30 |
| ▸ | TLR2 | O60603 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17083472 | 0.97 | CD22 (0.34) | CD22 | |
| SCHEMBL5531719 | 0.92 | CD22 (0.36) | CD22TLR2 | |
| SCHEMBL5529701 | 0.92 | CD22 (0.33) | CD22MAG | |
| SCHEMBL17083471 | 0.89 | CD22 (0.32) | CD22 | |
| SCHEMBL5529719 | 0.88 | CD22 (0.33) | CD22 | |
| SCHEMBL5533916 | 0.88 | CD22 (0.34) | CD22 | |
| SCHEMBL12341461 | 0.88 | CD22 (0.39) | CD22MAG | |
| SCHEMBL17083475 | 0.86 | CD22 (0.32) | CD22 | |
| SCHEMBL13402334 | 0.85 | CD22 (0.38) | CD22MAG | |
| SCHEMBL12341474 | 0.84 | CD22 (0.37) | CD22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170281785-A1 | GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES | NOVO NORDISK A/S (DK) | 2017-10-05 | — | — | US | disclosed |
| US-20170136104-A1 | GLYCOPEGYLATED FACTOR IX | NOVO NORDISK AS (DK) | 2017-05-18 | — | — | US | disclosed |
| US-20160361427-A1 | Glycopegylated Factor IX | NOVO NORDISK AS (DK) | 2016-12-15 | — | — | US | disclosed |
| US-20160184412-A1 | Glycopegylated Factor IX | NOVO NORDISK AS (DK) | 2016-06-30 | — | — | US | disclosed |
| US-20160158319-A1 | REMODELING AND GLYCOPEGYLATION OF FIBROBLAST GROWTH FACTOR (FGF) | NOVO NORDISK A/S (DK) | 2016-06-09 | — | — | US | disclosed |
| US-9200049-B2 | Remodeling and glycopegylation of fibroblast growth factor (FGF) | NOVO NORDISK A/S (DK) | 2015-12-01 | — | — | US | disclosed |
| US-20150125437-A1 | Glycopegylated Factor IX | NOVO NORDISK AS (DK) | 2015-05-07 | — | — | US | disclosed |
| US-8791070-B2 | Glycopegylated factor IX | NOVO NORDISK A/S (DK) | 2014-07-29 | — | — | US | disclosed |
| US-8791066-B2 | Branched PEG remodeling and glycosylation of glucagon-like peptide-1 [GLP-1] | NOVO NORDISK A/S (DK) | 2014-07-29 | — | — | US | disclosed |
| US-20140154230-A1 | Glycopegylated Factor IX | NOVO NORDISK A/S (DK) | 2014-06-05 | — | — | US | disclosed |
| US-20140112903-A1 | Glycopegylated Factor IX | NOVO NORDISK A/S (DK) | 2014-04-24 | — | — | US | disclosed |
| US-8633157-B2 | Glycopegylated erythropoietin | NOVO NORDISK A/S (DK) | 2014-01-21 | — | — | US | disclosed |
| US-8632770-B2 | Glycopegylated factor IX | NOVO NORDISK A/S (DK) | 2014-01-21 | — | — | US | disclosed |
| US-20130137157-A1 | GLYCOPEGYLATED FACTOR VII AND FACTOR VIIA | NOVO NORDISK A/S (DK) | 2013-05-30 | — | — | US | disclosed |
| US-20130059780-A1 | BRANCHED PEG REMODELING AND GLYCOSYLATION OF GLUCAGON-LIKE PEPTIDE-1 [GLP-1] | BIOGENERIX AG (DE) | 2013-03-07 | — | — | US | disclosed |
| US-20120172300-A1 | REMODELING AND GLYCOPEGYLATION OF FIBROBLAST GROWTH FACTOR (FGF) | NOVO NORDISK A/S (DK) | 2012-07-05 | — | — | US | disclosed |
| US-20110318780-A1 | ENZYMATIC MODIFICATION OF GLYCOPEPTIDES | BIOGENERIX AG (DE) | 2011-12-29 | — | — | US | disclosed |
| US-20110003744-A1 | Glycopegylated Erythropoietin Formulations | NOVO NORDISK A/S (DK) | 2011-01-06 | — | — | US | disclosed |
| US-20100330060-A1 | GLYCOPEGYLATED FACTOR IX | NOVO NORDISK A/S (DK) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059780-A1 | BRANCHED PEG REMODELING AND GLYCOSYLATION OF GLUCAGON-LIKE PEPTIDE-1 [GLP-1] | GLP1R, GIPR, IAPP | CD22 407/4885MAG 741/4885TLR2 639/4885 |
| US-20160158319-A1 | REMODELING AND GLYCOPEGYLATION OF FIBROBLAST GROWTH FACTOR (FGF) | FGF2, FGF1, FGFR1 | CD22 392/4885MAG 711/4885TLR2 1771/4885 |
| US-20120172300-A1 | REMODELING AND GLYCOPEGYLATION OF FIBROBLAST GROWTH FACTOR (FGF) | FGF2, FGF1, FGFR1 | CD22 392/4885MAG 711/4885TLR2 1771/4885 |
| US-20100330060-A1 | GLYCOPEGYLATED FACTOR IX | F9, F13A1, F13B | CD22 382/4885MAG 212/4885TLR2 1527/4885 |
| US-20160361427-A1 | Glycopegylated Factor IX | F9, F13A1, F13B | CD22 514/4885MAG 234/4885TLR2 2281/4885 |
| US-20170136104-A1 | GLYCOPEGYLATED FACTOR IX | F9, F13A1, F13B | CD22 514/4885MAG 234/4885TLR2 2281/4885 |
| US-20110003744-A1 | Glycopegylated Erythropoietin Formulations | EPOR, UGGT1, GNE | CD22 375/4885MAG 298/4885TLR2 1342/4885 |
| US-20160184412-A1 | Glycopegylated Factor IX | F9, F13A1, F13B | CD22 501/4885MAG 235/4885TLR2 2287/4885 |
| US-20170281785-A1 | GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES | UGCG, B3GAT3, UGGT1 | CD22 367/4885MAG 119/4885TLR2 1958/4885 |
| US-20150125437-A1 | Glycopegylated Factor IX | F9, F13A1, F13B | CD22 514/4885MAG 234/4885TLR2 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.